Pipeline

Our pipeline of immune-modulating, clinical-stage product candidates are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation.

Program & Target	Therapeutic Area	Preclinical	Rights
Rilonacept IL-1α & IL-1β	Recurrent Pericarditis (breakthrough therapy designation)	Mid Phase 3	Worldwide (excluding the Middle East and North Africa)
Mavrilimumab GM-CSFRα	Giant Cell Arteritis	Phase 2	Worldwide
	CAR T Induced Cytokine Release Syndrome*	End Phase 1	Worldwide
	COVID-19 Pneumonia & Hyperinflammation^†	End Phase 1	Worldwide
Vixarelimab OSMRβ	Prurigo Nodularis	Phase 2	Worldwide
Vixarelimab OSMRβ	Diseases Characterized by Chronic Pruritus	Phase 2	Worldwide
KPL-404 CD40	T-Cell Dependent, B-Cell–Mediated Indications	Phase 1	Worldwide

*Clinical collaboration with Kite, a Gilead Company, in relapsed or refractory large B-cell lymphoma. Phase 2 trial expected to start in the second half of 2020. Kite will be the sponsor of the trial and will be responsible for its conduct.
^†Preparing for a potential registrational development program for mavrilimumab in COVID-19 pneumonia and hyperinflammation.

Every Second Counts!